News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Vetmedica, Inc. Acquires Licensing Rights For Artilysin® Technology From Lysando AG



8/12/2014 8:50:20 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

REGENSBURG, Germany--(BUSINESS WIRE)--Artilysin®, a new and innovative technological approach in the fight against pathogenic and multi-resistant bacteria, developed by the research & development company Lysando, has arrived in the pharmaceutical industry. Boehringer Ingelheim Vetmedica has secured the licensing rights for the technology platform Artilysin®. The company is hopeful to receive significant momentum and solutions from this new substance class for the problem of multi-resistant bacteria, which also is an increasing threat to the animal world.

Artilysin®s are proteins that, through a physical mechanism, selectively eliminate pathogenic, multi-resistant and persisting bacteria. By way of license, Boehringer Ingelheim Vetmedica is taking advantage of the possibilities presented by this technology. The scope of applications for Artilysin®s spans from human and animal medicine to the food industry and the area of hygiene. They work quickly and with their “friend or foe” identification very specifically and are completely biodegradable. Additionally, no resistances occurred during the expansive studies. Multi-resistant bacteria pose a significant threat to health due to the increasing ineffectiveness of antibiotics. The EU Commission estimates the annual number of deaths caused by multi-resistant bacteria at 25,000. Massive economic effects are linked to this fact.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES